Annual Cash & Cash Equivalents
$3.25 M
-$23.23 M-87.72%
September 30, 2024
Summary
- As of February 8, 2025, CTXR annual cash & cash equivalents is $3.25 million, with the most recent change of -$23.23 million (-87.72%) on September 30, 2024.
- During the last 3 years, CTXR annual cash & cash equivalents has fallen by -$66.82 million (-95.36%).
- CTXR annual cash & cash equivalents is now -95.36% below its all-time high of $70.07 million, reached on September 30, 2021.
Performance
CTXR Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Cash And Cash Equivalents
$3.25 M
-$14.66 M-81.84%
September 30, 2024
Summary
- As of February 8, 2025, CTXR quarterly cash and cash equivalents is $3.25 million, with the most recent change of -$14.66 million (-81.84%) on September 30, 2024.
- Over the past year, CTXR quarterly cash and cash equivalents has dropped by -$14.66 million (-81.84%).
- CTXR quarterly cash and cash equivalents is now -97.19% below its all-time high of $115.66 million, reached on June 30, 2021.
Performance
CTXR Quarterly Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash And Cash Equivalents Formula
Cash & Cash Equivalents = Cash + Short-Term Investments
CTXR Cash And Cash Equivalents Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -87.7% | -81.8% |
| 3 y3 years | -95.4% | -81.8% |
| 5 y5 years | -58.8% | -81.8% |
CTXR Cash And Cash Equivalents Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -95.4% | at low | -95.0% | at low |
| 5 y | 5-year | -95.4% | at low | -97.2% | +17.0% |
| alltime | all time | -95.4% | -100.0% | -97.2% | -100.0% |
Citius Pharmaceuticals Cash And Cash Equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2024 | $3.25 M(-87.7%) | $3.25 M(-81.8%) |
| Jun 2024 | - | $17.91 M(+42.6%) |
| Mar 2024 | - | $12.56 M(-38.3%) |
| Dec 2023 | - | $20.35 M(-23.2%) |
| Sep 2023 | $26.48 M(-36.5%) | $26.48 M(-20.4%) |
| Jun 2023 | - | $33.28 M(+14.5%) |
| Mar 2023 | - | $29.07 M(-21.2%) |
| Dec 2022 | - | $36.89 M(-11.6%) |
| Sep 2022 | - | $41.71 M(-13.2%) |
| Sep 2022 | $41.71 M(-40.5%) | - |
| Jun 2022 | - | $48.04 M(-13.8%) |
| Mar 2022 | - | $55.76 M(-14.8%) |
| Dec 2021 | - | $65.42 M(-6.6%) |
| Sep 2021 | $70.07 M(+405.6%) | $70.07 M(-39.4%) |
| Jun 2021 | - | $115.66 M(+11.5%) |
| Mar 2021 | - | $103.70 M(+2314.0%) |
| Dec 2020 | - | $4.30 M(-69.0%) |
| Sep 2020 | $13.86 M(+75.6%) | $13.86 M(+62.7%) |
| Jun 2020 | - | $8.52 M(+96.3%) |
| Mar 2020 | - | $4.34 M(+56.1%) |
| Dec 2019 | - | $2.78 M(-64.8%) |
| Sep 2019 | $7.89 M(-14.0%) | $7.89 M(+75.0%) |
| Jun 2019 | - | $4.51 M(+41.0%) |
| Mar 2019 | - | $3.20 M(-54.6%) |
| Dec 2018 | - | $7.04 M(-23.3%) |
| Sep 2018 | $9.18 M | $9.18 M(+232.5%) |
| Jun 2018 | - | $2.76 M(-44.9%) |
| Date | Annual | Quarterly |
|---|---|---|
| Mar 2018 | - | $5.01 M(-32.1%) |
| Dec 2017 | - | $7.37 M(+130.0%) |
| Sep 2017 | $3.20 M(+988.3%) | $3.20 M(+1512.5%) |
| Jun 2017 | - | $198.70 K(+225.2%) |
| Mar 2017 | - | $61.10 K(+30.6%) |
| Dec 2016 | - | $46.80 K(-84.1%) |
| Sep 2016 | $294.40 K(-56.5%) | $294.40 K(-81.9%) |
| Jun 2016 | - | $1.63 M(-56.7%) |
| Mar 2016 | - | $3.76 M(+1235.3%) |
| Dec 2015 | - | $281.50 K(-58.4%) |
| Sep 2015 | $676.10 K(-56.4%) | $676.10 K(-28.9%) |
| Jun 2015 | - | $951.00 K(+25.1%) |
| Mar 2015 | - | $760.40 K(-7.0%) |
| Dec 2014 | - | $817.20 K(-47.3%) |
| Sep 2014 | $1.55 M(>+9900.0%) | $1.55 M(>+9900.0%) |
| Jun 2014 | - | $0.00(0.0%) |
| Mar 2014 | - | $0.00(0.0%) |
| Dec 2013 | - | $0.00(0.0%) |
| Sep 2013 | $0.00(-100.0%) | $0.00(0.0%) |
| Jun 2013 | - | $0.00(-100.0%) |
| Mar 2013 | - | $100.00(0.0%) |
| Dec 2012 | - | $100.00(0.0%) |
| Sep 2012 | $100.00(-50.0%) | $100.00(-50.0%) |
| Jun 2012 | - | $200.00(>+9900.0%) |
| Mar 2012 | - | $0.00(-100.0%) |
| Dec 2011 | - | $200.00(0.0%) |
| Sep 2011 | $200.00 | $200.00(+100.0%) |
| Jun 2011 | - | $100.00 |
FAQ
- What is Citius Pharmaceuticals annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for Citius Pharmaceuticals?
- What is Citius Pharmaceuticals annual cash & cash equivalents year-on-year change?
- What is Citius Pharmaceuticals quarterly cash and cash equivalents?
- What is the all time high quarterly cash and cash equivalents for Citius Pharmaceuticals?
- What is Citius Pharmaceuticals quarterly cash and cash equivalents year-on-year change?
What is Citius Pharmaceuticals annual cash & cash equivalents?
The current annual cash & cash equivalents of CTXR is $3.25 M
What is the all time high annual cash & cash equivalents for Citius Pharmaceuticals?
Citius Pharmaceuticals all-time high annual cash & cash equivalents is $70.07 M
What is Citius Pharmaceuticals annual cash & cash equivalents year-on-year change?
Over the past year, CTXR annual cash & cash equivalents has changed by -$23.23 M (-87.72%)
What is Citius Pharmaceuticals quarterly cash and cash equivalents?
The current quarterly cash and cash equivalents of CTXR is $3.25 M
What is the all time high quarterly cash and cash equivalents for Citius Pharmaceuticals?
Citius Pharmaceuticals all-time high quarterly cash and cash equivalents is $115.66 M
What is Citius Pharmaceuticals quarterly cash and cash equivalents year-on-year change?
Over the past year, CTXR quarterly cash and cash equivalents has changed by -$14.66 M (-81.84%)